The bill directs the Secretary of Veterans Affairs to produce a congressional report that assesses how often amyotrophic lateral sclerosis (ALS) occurs among veterans, describes current VA and CDC services, identifies gaps, and lays out strategies to reduce ALS incidence and prevalence in the veteran population. It also asks the VA to propose ways to let veterans receiving VA ALS care participate in VA-sponsored clinical trials and to recommend any legislative fixes needed to address shortfalls.
This is a narrow, implementation-focused statute: it ties VA reporting to a named CDC data resource and converts a one-off assessment into an ongoing monitoring obligation. For health system leaders, researchers, and VA program managers, the bill creates an explicit expectation that the VA and CDC coordinate surveillance, evaluate resource deficits, and move from assessment toward testable prevention and trial-enrollment pathways.
At a Glance
What It Does
The bill requires the VA to submit an initial report to Congress within one year that assesses ALS incidence/prevalence in veterans, inventories services and deficiencies, and proposes strategies to develop and test risk-reduction interventions and clinical-trial participation pathways; it further requires VA to track ALS cases using the CDC’s ALS registry and biorepository and to provide updates every three years.
Who It Affects
Primary actors are the Department of Veterans Affairs (clinical operations, research and policy offices) and the Centers for Disease Control and Prevention (registry and biorepository managers); affected populations include veterans diagnosed with ALS and VA clinicians and researchers who run ALS care and trials.
Why It Matters
The statute creates a federal data-and-reporting baseline tying VA surveillance to an existing CDC registry, pushes the VA toward operational solutions for prevention and trial access, and gives Congress a recurring informational lever to shape funding and program decisions for veterans’ ALS care and research.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill imposes a short, specific analytic assignment on the Department of Veterans Affairs: produce a report that measures how common ALS is among people the VA defines as veterans, describe what VA and the CDC currently provide in terms of services and support, point out where those services fall short, and lay out realistic strategies to reduce disease incidence and prevalence. The report must also propose how veterans receiving ALS care from VA clinics could be routed into VA-sponsored clinical trials and research projects.
Operationally, the law names the Centers for Disease Control and Prevention’s ALS registry and biorepository as the data source the VA must use to track prevalence; it also requires the VA to consult with the CDC Director when preparing the report. The statute converts the exercise from a single snapshot into a monitoring program by requiring a full update three years after the initial report and subsequent three-year updates thereafter.For VA program managers, the bill translates into defined deliverables: assemble prevalence estimates using registry and clinical data, conduct an inventory of support services (including care coordination, rehabilitation, and family support), identify resource shortfalls, and propose prioritized, testable interventions to reduce risk.
On the research side, the requirement to build a pathway for clinical-trial participation implies creating referral, consent, and data-sharing workflows between VA clinics and VA research units or trial sponsors.Because the statute asks for strategies to develop and test risk-reduction measures—not for immediate implementation of a specific prevention program—it places the VA in a planning and coordination role. Practical implementation will require the VA to negotiate data access and privacy terms with the CDC, align internal research offices (for example, VA ORD and research networks) with clinical operations, and decide how to resource pilot studies or surveillance enhancements without explicit funding in the text.
The Five Things You Need to Know
The VA must deliver an initial report to Congress within one year of enactment and then provide updates every three years thereafter.
The statute requires the VA to prepare the report in consultation with the Director of the Centers for Disease Control and Prevention.
The VA must use the CDC’s ALS registry and biorepository to track ALS prevalence among veterans.
The report must include: an assessment of incidence/prevalence, a description of VA and CDC resources/support, documented deficiencies, a strategy to develop and test risk‑reduction interventions, a strategy to enable veteran participation in VA-sponsored clinical trials, and legislative recommendations.
The bill directs the VA to propose a concrete pathway for veterans receiving ALS care in VA clinics to participate in VA-sponsored clinical trials and research.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s name — "Veterans with ALS Reporting Act" — which is procedural but matters because sponsors and implementing offices will use the short title in administrative references and budget documents.
Report content and CDC consultation
Specifies the substantive contents the VA report must contain: (1) an assessment of ALS incidence and prevalence in veterans; (2) a description of resources and support the CDC and VA provide to veterans with ALS; (3) any deficiencies in those resources; (4) a strategy to develop and test risk-reduction approaches; (5) a strategy to create a pathway for VA clinic patients to join VA-sponsored trials; and (6) recommendations for new legislation. The provision requires the VA to consult with the CDC Director while preparing the report, which establishes a formal coordination expectation rather than leaving collaboration informal.
Use of CDC ALS registry and biorepository for tracking
Directs the VA to track ALS prevalence in veterans using the CDC’s ALS registry and associated biorepository. Practically, that requires the VA to map internal patient records to the registry, negotiate access or data-use agreements, and ensure the VA’s analytic teams can work with registry case definitions and biospecimen-linked metadata.
Periodic updates
Requires a follow-up report not later than three years after enactment and updates every three years thereafter that provide updated prevalence information and any changes in the VA’s strategies or resource posture. This establishes a recurring duty to Congress rather than a one-time study, creating a standing information stream policymakers can use to evaluate progress or request further action.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with ALS — the statute pressures agencies to identify resource gaps and propose ways to expand clinical-trial access and tailored prevention strategies, which can improve care options over time.
- VA clinicians and care coordinators specializing in neuromuscular disease — they gain a mandated inventory of services and an explicit signal that VA leadership should prioritize ALS-related workflows and trial referral pathways.
- VA and non-VA researchers studying ALS — mandated use of the CDC registry and a statutory push toward testing risk-reduction strategies will expand available surveillance data and create opportunities for collaborative pilot studies.
- Congressional appropriations and oversight staff — the recurring reports create a structured evidence base for funding decisions and oversight hearings, simplifying evaluation of program performance.
Who Bears the Cost
- Department of Veterans Affairs administration and staff — compiling the report, negotiating data agreements with CDC, and running ongoing surveillance and pilot strategy work will consume staff time and likely require reallocation of resources.
- CDC registry and biorepository managers — increased VA reliance on these assets will raise data-request volumes and administrative overhead for linkage and data-sharing operations.
- VA research offices and clinical trial units — creating and operating referral pathways and pilot risk-reduction trials will impose operational and possibly financial burdens unless Congress provides additional resources.
- State and private clinical trial partners (if engaged) — coordinating with VA clinics and complying with VA processes will introduce administrative interfaces and expectations that can increase trial setup complexity.
Key Issues
The Core Tension
The bill forces a choice between urgent action and scientific caution: Congress and veterans want plans to lower ALS risk and better trial access now, but the evidence about modifiable ALS causes is limited and VA/CDC capacities are constrained—so the statute demands actionable strategies while leaving agencies to bridge substantial funding, data-sharing, and scientific-evidence gaps.
The bill is tightly scoped and light on implementation detail, which creates both flexibility and risk. It mandates strategies to "develop and test" risk-reduction interventions but does not specify standards for what constitutes a validated strategy, which agency leads pilot testing, or how pilots are funded.
That gap means the VA could produce high-quality analytic reports without delivering concrete pilots unless Congress or VA leadership commits resources and assigns operational responsibility.
Data and privacy challenges are another practical hurdle. The law requires use of the CDC’s ALS registry and biorepository; linking those datasets to VA clinical records for prevalence estimation and trial-referral workflows will require data-use agreements, matching protocols, and human subjects protections.
The bill does not address consent processes for biospecimen use in VA research nor does it allocate funding for the technical work of record linkage, so implementation could be slowed by institutional review board review cycles and interagency negotiation.
Finally, there is a scientific constraint: ALS etiology is incompletely understood and established modifiable risk factors are limited. Mandating development and testing of risk-reduction strategies before the evidence base expands creates a timing tension — the VA will need to design plausible, ethically defensible pilot interventions in an area where prevention signals are weak, which may yield equivocal results and complicate next-step policymaking.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.